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Priority pharmaceutical micropollutants and feasible management 1 
initiatives to control water pollution from the perspective of 2 
stakeholders in metropolis of southern Brazil 3 
 4 
Abstract 5 
The search for common agreement between stakeholders is one of the biggest 6 
challenges for solving environmental problems. There are different views, perceptions, 7 
knowledge and sectoral goals for these stakeholders. In complex environmental 8 
problems, such as the management of pharmaceutical micropollutants, it is essential to 9 
establish the intersectoral and individual sector priorities for a collective approach to 10 
the problem. This research aimed to identify priority micropollutants for intervention 11 
initiatives, and the management goals of the stakeholders involved in the ‘product 12 
chain’ of pharmaceuticals, in the region of Curitiba, Brazil. First, the most consumed 13 
pharmaceutical micropollutants in the region and those previously detected in water 14 
were identified and a ‘long list’ with 40 pharmaceuticals was drawn up for prioritization 15 
by stakeholders. Stakeholders of region were selected by intentional sampling and were 16 
invited to a workshop that was designed to list, by consensus, priority micropollutants 17 
and objectives for their management. The event was attended by 37 stakeholders from 18 
different sectors. It was divided into two stages: the first stage was a multisectoral 19 
discussion to select the priority pharmaceutical micropollutants; the second stage a 20 
sectoral discussion to establish management objectives to control and reduce the 21 
presence of these pollutants in waters. The meeting generated a coherent prioritization 22 
of pharmaceuticals where ethinyl estradiol, ciprofloxacin, ibuprofen, diclofenac, 23 
estradiol, caffeine and fluoxetine were prioritized and their importance was justified. 24 
The main sectoral goals prioritized were related with the drug take-back program, 25 
characterization of the presence of pharmaceuticals in the sanitation cycle and the 26 
creation of a permanent multi-sector discussion environment for the theme. The 27 
multisectoral definition, established collectively by consensus, of management priorities 28 
is promising and this strategic approach can be replicated in other developing countries. 29 
Key-words: Pharmaceutical micropollutants    Prioritization process   Water 30 
management    Water pollution control     Stakeholder engagement    Urban 31 
environmental management   32 
 33 
INTRODUCTION 34 
Pharmaceuticals are absolutely essential to the medical demands of animals and 35 
humans, but paradoxically, the same properties that ensure the therapeutic effects of 36 
these substances are those that can cause the toxicity or bioaccumulative potential of 37 
their traces in the environment (Halling-Sørensen et al. 1998; Santos et al. 2010). 38 
Exposure to traces of medical substances, intentionally or unintentionally released into 39 
the environment, has received attention worldwide. The problem was initially 40 
highlighted in the 1970s in the USA and about a decade later in the United Kingdom, 41 
Revised Munuscript 06/06/2020 
with advances in analytical techniques for detection and laboratory measurement 42 
(Santos et al. 2010). But it was from the mid-1990s that investigations on the subject 43 
were intensified, showing cause-effect responses of these residues on the environment 44 
and human health (Kümmerer 2009; Qian et al. 2015; Tiedeken et al. 2017). At present, 45 
the focus is primarily on urban rivers, since the characteristics of the ‘product chain’ 46 
(Helwig 2018, p.200) of pharmaceutical production and consumption are most likely to 47 
result in high concentrations of residue where high population densities and low 48 
environmental dilution co-occur (Helwig 2016). Since in Brazil only 46% of the sewage is 49 
treated and only 21 municipalities, all located in the 100 largest cities in the country, 50 
treat more than 80% of the sewage (SNIS 2018), the priority of the sanitation sector is 51 
still focused on the removal of macropollutants, i.e. dissolved organic carbon, nitrogen 52 
and phosphorus, from industrial and household effluents. Among the group of 53 
micropollutants, the demands of the productive sector (agriculture and industry) for 54 
agrochemicals and metals has led to those residues being considered priorities for the 55 
national context. A previous study (Barcellos et al. 2019a, p. 76), carried out with 32 56 
stakeholders from different sectors of society (community, academia, government and 57 
productive sector) in the Curitiba/Brazil region, showed that the most important aquatic 58 
micropollutants are pesticides, followed by heavy metals and then pharmaceuticals.  59 
There are already management initiatives for agrochemicals and heavy metals in 60 
the waters in Brazil, implemented via legal instruments that establish limits for the 61 
maximum permissible concentrations of these compounds both in natural waters (Brazil 62 
2005) and water supply systems (Brazil 2017). Despite an emerging scientific consistency 63 
in the international literature on the environmental effects of some pharmaceutical 64 
compounds, such as 17-alpha ethinylestradiol (Owen and Jobling 2013; Gilbert 2013), 65 
there are as yet no regulations and standards to drive monitoring, control and 66 
minimization of its residues in Brazil. This is largely true elsewhere in the world as well, 67 
although several pharmaceuticals are on the EU ‘Watch List’ and Article 8c of Directive 68 
2008/105/EC (amended by Directive 2013/39/EU) obliges the European Commission to 69 
develop a strategic approach to water pollution from pharmaceutical substances and 70 
some countries have started putting in place national regulations (Küster and Adler 71 
2014). As the concentrations of pharmaceuticals reported in Brazilian surface waters 72 
have been relatively high, and certain pollutants have indeed also been found in the 73 
water supply in significant concentrations (Dias 2014; Böger et al. 2015; Lima et al. 2017; 74 
Reis et al. 2019), there is a need to prioritize pharmaceutical substances for monitoring 75 
and intervention.  Efforts to establish a comprehensive prioritization of pharmaceuticals 76 
in Brazil and in developing countries are still incipient (Barcellos et al. 2019b). 77 
Where a lack of data on the range, volume and toxicities of pharmaceuticals 78 
consumed hinders a strictly risk-based approach, a mix of published data and ‘expert 79 
input’ can be used as a starting point (Helwig et al. 2013) for the prioritization of 80 
pharmaceuticals for monitoring or intervention.  In this study, we explore firstly how 81 
local stakeholders prioritize pharmaceuticals for the management of urban waters, and 82 
from there, we explore options for management initiatives.  83 
The entire management process can be considered collective and needs to be 84 
negotiated among the stakeholders. This is no different in the case of pharmaceutical 85 
micropollutants. The various groups involved in this issue have distinct and 86 
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complementary overviews, responsibilities and knowledge about the processes involved 87 
in the product chain of these pollutants. In order to validate such a collective approach, 88 
it is essential that the integration of these perceptions, priorities and manageable 89 
initiatives is discussed jointly by all these stakeholders. The topic of pharmaceutical 90 
pollution has not been widely discussed in Brazil so far, and in the incipient discussions 91 
that have been established, the sectorial nature of approaches and decisions remains 92 
(Barcellos et al. 2019a, p. 142). This study sought to bring stakeholders together to 93 
further this integration of perspectives in order to bring about a collective approach to 94 
management. 95 
MATERIALS AND METHOD 96 
This study was conducted in the metropolitan region of Curitiba, the ninth largest 97 
metropolitan region in Brazil, with about 3.5 million inhabitants (IBGE 2016). Curitiba 98 
and the metropolitan region have an integrated water supply system, so that the city's 99 
drinking water also comes from the metropolitan region (SANEPAR 2013). Water 100 
management in Brazil is the responsibility of Union (national authority) and States 101 
(regional authority) while the land use and "to combat pollution in all its forms" is the 102 
responsibility of municipalities (Brazil 1988). The city of Curitiba is the capital of the 103 
Parana State, has around 2 million inhabitants, is the largest city of southern Brazil and 104 
the eighth most populous in the country (IBGE 2019). The city has a world-renowned 105 
history of urban planning and management and has won several international awards in 106 
recognition of the initiatives in favor of the environment and the quality of life of its 107 
citizens (Mega 2010; Macedo 2013). It is also the Brazilian capital with the best basic 108 
sanitation in the country, with 94% sewage coverage, 100% of treated water supply for 109 
the population and 100% waste collection (SNIS 2018). As such, the city was selected for 110 
the possibility of exploring the potential for innovation in management technologies and 111 
environmental planning. 112 
A workshop was organized with stakeholders to prioritize pharmaceutical 113 
micropollutants, as well as to jointly identify feasible management initiatives. Prior to 114 
this workshop, two selection processes was take place: a ‘long list’ of possible priority 115 
pharmaceutical products was drawn up to begin the selection and classification process 116 
and presented to stakeholders, and, of course, the stakeholders in the Curitiba region 117 
themselves have been identified and approached as potential workshop participants.  118 
Initial pharmaceutical micropollutants long list 119 
The ‘long list’ of pharmaceuticals was established with a view to selecting 120 
pharmaceuticals that might be likely to be ‘priorities for intervention’ by participants. 121 
Establishment of a ‘long list’ from thousands of pharmaceuticals available on the market 122 
is not straightforward and various criteria, including consumption level, ‘expert choice’, 123 
previous detections, and known toxicities can be used in this process (Helwig et al. 124 
2013). In the current research, two separate approaches were used. 125 
Firstly, in order to represent ‘expert choice’ and include an element of 126 
(perceived) risk to the environment, the literature was reviewed to determine which 127 
pharmaceutical micropollutants had been monitored in the rivers of the Metropolitan 128 
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Region of Curitiba and to identify minimum and maximum concentrations for these 129 
compounds. It was established that only 27 compounds from 8 different classes 130 
(hormones, antihypertensives, anti-inflammatories, analgesics, psychotropics, 131 
metabolites, lipid regulators, stimulants and food/cosmetics preservatives (Ide et al. 132 
2013; Kramer et al. 2015; Osawa et al. 2015; Böger et al. 2018; Barcellos et al. 2019a, p. 133 
66) had been monitored in this region. Several shortcomings to this first approach are 134 
acknowledged. Firstly, the list of pharmaceutical products resulting from review 135 
included only those already monitored and detected in surface waters, which represents 136 
a tiny fraction of all pharmaceuticals on the market. This constraint is exacerbated by 137 
the fact that many researchers, for reasons of convenience, select analytes that have 138 
already been reported in the environment - a phenomenon known as the ‘Matthew 139 
effect’ (Merton 1988) – or for which there is a readily available analytical method. 140 
Secondly, beyond their detection, there is no attempt to prioritize these substances or 141 
to establish their actual environmental risk. Thirdly, the list does not represent in any 142 
way the multisectoral interests or concerns of the various stakeholder groups. 143 
Nevertheless, as a starting point for discussions, a list of pharmaceuticals detected in 144 
the local environment was thought to be useful.   145 
The second approach was based on pharmaceutical consumption patterns and 146 
sought to establish which pharmaceuticals are most commonly consumed in the region. 147 
Pharmaceuticals may be bought by the general population, freely dispensed by medical 148 
staff in Municipal Health Units (MHU) or dispensed and used in hospitals (the 149 
pharmaceuticals used and dispensed by hospitals were not considered in this analysis, 150 
as there are no data available). The pharmaceutical consumption data in Curitiba used 151 
in this research refer to the period of 2016 and 2017 and were extracted from a research 152 
already published (Barcellos et al. 2019a, p. 78-99). The level of consumption of a 153 
pharmaceutical is a poor indicator of the environmental risk posed by its residues in the 154 
environment, which depends on many factors including metabolism (including the 155 
extent to which the pharmaceutical is excreted as parent compound or as metabolites), 156 
persistence in the environment, potential for bioaccumulation and toxicity. But just like 157 
the previous list of compounds already found in water bodies, the list of top-selling and 158 
distributed pharmaceuticals is an important starting point, not only because it may allow 159 
inference of which pharmaceuticals are likely to be present in the waters but also 160 
because they are likely to be familiar to workshop participants. 161 
From these two initial lists, 40 active ingredients of pharmaceutical products 162 
were identified as potential priorities for stakeholders (this list can be found in 163 
Supplemental Data). The pharmaceuticals selected were those: 1) with a relevant 164 
position in the consumption ranking (sale in pharmacies + free distribution in health 165 
units); 2) present in the waters of the region in concentration and with possible 166 
environmental effects (information evaluated from the study of each molecule by Wiki 167 
Pharma data base). Among the 40 selected, 10 active principles had already been 168 
monitored and detected in the waters of the region. For the 40 pharmaceuticals 169 
selected, information was sought on the percentage excreted unchanged via urine 170 
(Bernareggi 1998; Johnson and Williams 2004; Ashley and Currie 2009; Lucena 2013; 171 
Cunha 2014; EMC 2017) and the ecotoxicological LOEC - lowest observed effect 172 
concentration - (Wiki Pharma 2018) of each compound to make available to 173 
stakeholders. This list was sent to all invited stakeholders, who were asked to indicate, 174 
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in their own view, which 10 compounds they considered to be a priority and to bring 175 
this list of the 10 along to the workshop. The use of these initials list was designed to 176 
guide the discussion, but stakeholders could select other pharmaceuticals that were not 177 
included in the lists. 178 
Selection of Stakeholders  179 
The stakeholders were selected by intentional sampling, following a procedure 180 
similar of previous research (Doerr-MacEwen and Haight 2006), we sought participants 181 
from two broad groups: those who have contributed to the literature on micropollutants 182 
in the region, and those who play a role in the production and consumption of 183 
pharmaceuticals and their subsequent management in (waste) waters. 184 
To identify them, an exploratory research was initially carried out for academic 185 
papers published by researchers from institutions located in the region of Curitiba. The 186 
curricula vitae of these researchers were accessed by 'Lattes Platform' (a system that 187 
reports academical and scientific information of researchers working in Brazil) and, 188 
through the personal list of publications and research projects, other research 189 
collaborators were identified who were listed as possible participants. 190 
Secondly, governmental institutions with interest in the management of water 191 
resources were identified based on previous work (Bracht 2008; Lara 2014; Barcellos et 192 
al. 2019a, p. 74). Additionally, other institutions were identified through internet 193 
research, including those related to the productive sector and the hospital and 194 
pharmaceutical sectors. 195 
The representatives of the selected institutions were divided into 5 groups: 196 
decision makers, generally representing local and state government; researchers, 197 
belonging to the 4 main local universities; pharmaceutical sector (unions, class councils 198 
and institutions representing the category) and representatives from a hospital 199 
(healthcare workers appointed by the manager); pharmaceutical industry and finally the 200 
water industry, represented by the Parana State Sanitation Company - SANEPAR (a list 201 
of institutions and the number of invitees of each group stakeholders can be found in 202 
Supplemental Data).  203 
The Prioritization Process 204 
A workshop was held involving all stakeholders. This was divided into two 205 
phases: the first phase sought to identify 5 pharmaceuticals prioritized for monitoring 206 
and management to reduce their residues and to justify this selection; in the second 207 
phase, possible management objectives and initiatives for pollution control were 208 
identified, whereby stakeholders also indicated the stages and temporal scale to 209 
implement these. The discussions in both the first part of the event and the second were 210 
based on scientific evidence (Figure 1). In the first phase of the event, the 'long list' was 211 
sent to participants by email, two weeks before the event. While at the end of the first 212 
part of the event, the dynamics of the second phase were explained and participants 213 
were given the frame of management initiatives, adapted from the literature 214 
(Supplemental Data). Based on this frame, as the 'long list' in first phase, the participants 215 
were asked to bring a list of goals that, in their perception, could be achieved by their 216 
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own sector to reduce the concentration of pharmaceuticals in rivers. These materials 217 
(long list and frame of management initiatives) were useful to guide the discussion and 218 
enriched it at the working tables, where individual perceptions could be further 219 
developed. 220 
Figure 1 - Sequential diagram of the collective approach developed for prioritization on 221 
the management of pharmaceutical micropollutants. 222 
In order to allow more effective management of the discussions and to 223 
encourage a more productive participation of each participant, the initial group of 55 224 
invitees was divided into 2 subgroups in the first phase of the workshop, maintaining 225 
proportionality of each sector in each group of stakeholders. The two subgroups met on 226 
November 19 and 20, 2018, respectively for the first phase events. At each subgroup 227 
meeting, the guests were divided into four working tables. The composition of the tables 228 
was planned so that each table could count on the participation of a representative from 229 
each sector, allocated prior to the event with a random number generator (both in the 230 
first and second round), although this was not quite achieved as not all invitees 231 
attended: each of the subgroup meetings was attended by 17 participants each, totaling 232 
34 guests out of 55 stakeholders initially invited. Once consensus was obtained in 233 
working tables, the results were presented and discussed in a plenary session. The 234 
second phase of the process occurred on November 27, 2018. This phase followed the 235 
same methodology as the previous phase, but with the formation of sectoral working 236 
tables, instead of multisectoral negotiation. This phase was designed to be carried out 237 
with all 34 stakeholders who participated in the first phase (subgroups 1 and 2), but only 238 
22 participants attended the second phase. Of these 22 participants, 3 had not attended 239 
the first phase of the event.  The stakeholders this phase represented four sectors and 240 
were accordingly arranged at four working tables.  241 
Both in the second and in the first phase of the event, each working table had a 242 
mediator / rapporteur. They had the function of leading the discussion, if necessary, and 243 
reporting on its most important points. In the two phases of the event, one of the 244 
participants at each table was responsible for filling in a standard sheet with the results 245 
of the table by consensus. In the plenary sessions there was also a rapporteur. At the 246 
start of the plenary session of the first phase of the event, a free discussion was 247 
established. In the meantime, the support team calculated the values of the top seven 248 
(first round) and top five (second round) – seven and five points were assigned to the 249 
first in the ranking each table, six and four to the second and so on - of the four work 250 
tables, creating a single ranking for each round. It should be noted that the scoring 251 
systems were merely illustrative so that reflection and discussion could be established; 252 
consensus was the basic principle of the entire event. In the plenary sessions of the 253 
second phase of the event, the most important goal agreed by each sectoral table (first 254 
round), the ways to achieve it and the timeframe (second round) were read aloud to 255 
allow a moment for reflection and multisectoral discussion. At the end of the second 256 
plenary sessions at both the first and the second phase of the event, the Mentimeter® 257 
software was used to perceive the individual opinion of the participants.  258 
PRIORITY PHARMACEUTICAL PRODUCTS FOR WASTE MANAGEMENT 259 
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The first result obtained was derived from the individual lists brought in by the 260 
invited stakeholders. For the construction of a classification, a scoring system was 261 
assigned to the individual lists, following the same logic as those developed for the top 262 
7 and 5. Scores in individual lists were summed by compound resulting in a ranking 263 
(Figure 2). It should be noted that exercise of classification of individual lists was carried 264 
out after the meetings, only in an exploratory way, and participants not have access this 265 
ranking. The lists were used in the working tables and delivered at the end of the event 266 
Figure 2 - Top 10 priority pharmaceuticals of according to the individual perceptions.  267 
A total of 65 different pharmaceuticals were mentioned on the individual lists. 268 
Those most frequently prioritized belonged to the following therapeutic groups: 269 
hormones, with four compounds (ehinylestradiol, estradiol, estrone and 270 
levonorgestrel), two of which were first and second in the ranking; anti-inflammatories 271 
(diclofenac and ibuprofen); antibiotics (amoxicillin and ciprofloxacin); an analgesic 272 
(paracetamol); a psychotropic (fluoxetine) and a stimulant (caffeine). Ciprofloxacin, 273 
which was not on the 'long list', was selected in many individual lists and ranked 11 in 274 
this initial exercise.  275 
The results of the first round of negotiation (Figures 3 and 4) – the closed meeting 276 
where working tables attempted to identify 7 pharmaceuticals as priorities - show that 277 
the second subgroup (Figure 4) of stakeholders had more difficulty to agree on the most 278 
important compounds compared to the first subgroup (Figure 3), with the final list of 279 
the subgroup 2 showing 13 pharmaceuticals whereas the of subgroup 1 showed only 8. 280 
The score of the first placed in the ranking was significantly lower in the subgroup 2, and 281 
there were also pharmaceuticals tied in the fourth, fifth and seventh position of the final 282 
list.   283 
In the subgroup 1 plenary, the focus of the discussions was what pharmaceuticals 284 
should be prioritized and what would be the criteria for choosing them. On the other 285 
hand, in the subgroup 2, the discussion was focused on the paradox: prioritizing specific 286 
pharmaceuticals based on their individual importance or identify markers for the various 287 
therapeutic groups. In this subgroup, virtually every working tables agreed that it would 288 
be better to prioritize markers rather than specific pharmaceuticals. Perhaps this is the 289 
most logical explanation for the greater balance in the list of the priority 290 
pharmaceuticals pointed out by subgroup 2. 291 
Figure 3 - Top 7 priority pharmaceuticals of according to stakeholders (First Round) 292 
subgroup 1. 293 
In the plenary session of the round, the results of the prioritization of each 294 
working table and the pharmaceuticals with the highest aggregated score (adding up 295 
the values of all working tables) were presented for general discussion. After the 296 
plenary, the groups returned to the working tables in order rank the top 5 297 
pharmaceuticals, based on the general ranking of the pharmaceuticals prioritized in the 298 
first round. 299 
Figure 4 - Top 7 priority pharmaceuticals of according to stakeholders (First Round) 300 
subgroup 2. 301 
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With a second round of discussion in the working tables, each table was able to 302 
produce a consensual ranking of five of the most important pharmaceutical products for 303 
the management of the waters of the region of Curitiba. The results of the second round 304 
of discussion were tabulated with the scoring system that was used to present the 305 
aggregated results of the four tables working in the plenary (Figure 5).  306 
Figure 5 – Top 5 priority pharmaceuticals for the subgroups 1 and 2 (Second Round). 307 
 Subgroup 1 agreed that antibiotics should be included as a group because 308 
antibiotic residues may represent important environmental and public health problems. 309 
It was agreed that the detection of antibiotics can be done indirectly, measuring the 310 
effect of bacterial resistance to pharmaceuticals, since this methodology has a low cost 311 
and an easy analytical procedure unlike the chromatographic methods. Ciprofloxacin 312 
was the antibiotic most indicated by the stakeholders, because its molecule remains 313 
active after treatment (it is persistent). Beta-lactam antibiotics, despite being listed as a 314 
priority in the literature, were discarded by stakeholders because they degrade easily in 315 
the environment (Mitchell et. 2014; Timm et. 2019). Fluoxetine was not indicated as a 316 
priority because, according to stakeholders, there are other pharmaceuticals whose 317 
impacts are more relevant. The anti-inflammatory nimesulide, widely used in Brazil, was 318 
mentioned by this subgroup in plenary, as it is a molecule that needs to be further 319 
studied regarding its potential risks to the environment, but is currently not recognized 320 
by the group as a priority. In the end, the subgroup 1 agreed that the order of 321 
prioritization was established more by the potential risks to the environment than by 322 
frequency of use. 323 
 324 
After the plenary session that identified the 5 priority pharmaceuticals for the 325 
management in subgroup 1, according to the aggregate score of the work tables (Figure 326 
5), a survey was carried out using the software Mentimeter®, in which the stakeholders 327 
were invited to answer, with their smartphones, a question about their satisfaction with 328 
the ranking produced. The results showed a high degree of satisfaction regarding the 329 
final ranking: 14 out of the 17 participants answered the question (three participants 330 
had to leave before the end of the discussion and so they did not answer the question), 331 
whereby four stated they were very satisfied, eight were satisfied, two were not entirely 332 
satisfied, and no one answer for the option "unsatisfied" or "very unsatisfied". The two 333 
stakeholders who were not entirely satisfied were a representative from the 334 
pharmaceutical industry and hospital. For the hospital representative, the 335 
dissatisfaction was due to the fact that the management of some priority molecules 336 
would require a very specific investment and a more macro view was needed. In the 337 
case of one of the representatives of the pharmaceutical industry the dissatisfaction was 338 
due to the fact that only two pharmaceuticals prioritized in their individual list were in 339 
the top 5 of the group. 340 
In the subgroup 2 plenary, one participant stated that in their perception it 341 
seemed reasonable and feasible to introduce legislation requiring monitoring of 342 
pharmaceutical micropollutants in urban river waters, with one representative 343 
compound for each pharmaceutical group. For him, the monitoring procedures would 344 
be feasible financially, since some institutions already have equipment to carry out the 345 
measurements. However, this was not the consensus among the various sectors 346 
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represented at the meeting. In the working tables of this subgroup, participants 347 
frequently suggested caffeine for inclusion in the list of priority pharmaceuticals, since 348 
it is an indicator pharmaceutical for the presence of sanitary effluents, which is the main 349 
vehicle of several pharmaceuticals for rivers (Figure 5). Caffeine has been shown to being 350 
a good indicator for the presence of other pharmaceutical compounds because, in 351 
addition to be a persistent molecule in the environment, it is present in many 352 
pharmaceuticals as an auxiliary substance (Daneshvar et al. 2012; Montagner et al. 353 
2014; Baz-Lomba et al. 2016; Alygizakis et al. 2016; Korekar et al. 2019). Another 354 
substance mentioned that could be used as an indicator was Carbamazepine: some 355 
experts have already used this compound as a monitoring alternative to Caffeine since 356 
it is also a persistent molecule and widely used in the pharmaceutical industry (Guo and 357 
Krasner, 2009; Wang and Wang, 2017; Dinis et al. 2017; Dvory et al. 2018). It was 358 
discussed by the group that it might be interesting to include as a priority the pair of 359 
anti-inflammatory pharmaceuticals, diclofenac and ibuprofen, as both are widely used 360 
at all times of the year. 361 
Again, with use of the software Mentimeter®, applying to the audience a final 362 
question about the overall satisfaction with the aggregated prioritization results (Figure 363 
5), most of the participating stakeholders agreed with the final ranking. Of the 17 364 
stakeholders 9 answered the question (eight participants had to leave before the end of 365 
the discussion and so they did not answer the question), where seven respondents said 366 
they were satisfied and two indicated the option "I am not entirely satisfied" with the 367 
priorities highlighted by the group.  For stakeholders who were not entirely satisfied 368 
were a representative from academia and a hospital. For the hospital representative the 369 
dissatisfaction was because two anti-inflammatory pharmaceuticals (ibuprofen and 370 
diclofenac) on the priority list would be too much - should be one or the other. In place 371 
of one, his would include an antineoplastic. For the academic stakeholder the 372 
dissatisfaction was because triclosan should be on the medication prioritization list, as 373 
it is an endocrine disruptor, bioaccumulative and in many countries, such as the USA and 374 
some European countries, it is already banned, while in Brazil it is still used as a 375 
preservative in hygiene products (shampoos, soaps, etc). 376 
There was a clear similarity (Figure 5) between the two lists of 5 priority 377 
compounds as identified in the two subgroups, which demonstrates the validity of the 378 
method since the stakeholders who participated in the two subgroups were different, 379 
with no contact between the groups. 380 
Table 1 shows the final score of the ranking pharmaceuticals identified as 381 
priorities by the stakeholders in this first phase of the workshop and the justifications 382 
that were given for their prioritization. Ethinylestradiol, ibuprofen, ciprofloxacin and 383 
diclofenac were identified by both subgroups as the four most important 384 
pharmaceuticals for water management. Regarding the fifth priority pharmaceutical, 385 
the hormone estradiol had a higher score (8), however, caffeine (7) and fluoxetine (6) 386 
had a very close score. Therefore, there are still doubts about the fifth substance to be 387 
prioritized.  388 
Table 1 – Priority pharmaceuticals for water management according to the stakeholders' 389 
perception. 390 
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*Ecotoxicological LOEC - Lowest Observed Effect Concentration. 391 
FEASIBLE MANAGEMENT GOALS 392 
The feasible goals for the management of the pharmaceutical micropollutants in 393 
the Curitiba region were discussed at the second phase of the workshop that took place 394 
on November 27, 2018. As mentioned, participation at this event was significantly lower, 395 
with only 22 participants out of about 34 expected stakeholders in attendance. One 396 
important and significant lack was the absence of the government sectoral group (policy 397 
makers): no representative of that sector attended the event.  398 
Not surprisingly, the individual goals were quite diverse, although they pointed 399 
in converging directions. Frequently suggested individual goals were: 400 
1. The full implementation of a drug take-back program of expired or obsolete 401 
pharmaceuticals. The scope of this initiative varied in the lists, which sometimes 402 
indicated a state scale of coverage (in the cities of Parana State), sometimes local 403 
(pharmacies and medical centers in Curitiba) and sometimes sectoral 404 
(encompassing pharmaceutical distributors); 405 
2. Periodic monitoring of pharmaceutical micropollutants in water supply and river 406 
basins. With regards to monitoring, the individual lists pointed out two 407 
directions: a) to monitor those of greater consumption; b) to create a working 408 
group to discuss and make feasible this activity, in terms of infrastructure and 409 
equipment, partnerships, costs and analytical methodologies; 410 
3. Development and testing of efficient treatments for the removal of priority 411 
pharmaceutical micropollutants in water and sewage. The scope of the proposal 412 
was to find efficient treatment for water industry, responsible for municipal 413 
water and sewage treatment, and pharmaceutical industries. In this goal, it was 414 
evident that participants saw this as academic research at this stage, because 415 
little was thought to be known about the viable and effective techniques of 416 
removal of these compounds; 417 
4. Multisector partnerships: academia, pharmaceutical sector, pharmaceutical and 418 
water industry as well, for the identification of priority compounds, development 419 
of analytical methodologies and the removal of these compounds; 420 
5. Universalization of sanitation systems including sewage networks and treatment 421 
plants; 422 
6. Implement a limit concentration for priority pharmaceutical micropollutants in 423 
rivers and water supply systems in the coming years; 424 
7. Evaluation of the internal processes of the pharmaceutical industry to reduce the 425 
generation of waste and consequently lower the concentration of emerging 426 
micropollutants in the effluents; 427 
8. Environmental education for the correct disposal of pharmaceuticals, rational 428 
use, and reduction of self-medication: this educational process would occur 429 
through recommendations on the packaging of pharmaceuticals and 430 
advertisements (newspapers, television, bus stops, etc.). 431 
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In the individual goals, as well as in those discussed at the sectoral working 432 
tables, the absence of public policy was a clear consequence of the absence of the 433 
government sector.  434 
The lists of individual goals presented a preview of what would be discussed at 435 
the sectoral tables, but the robustness and originality of the goals discussed at the table 436 
far outstripped those highlighted by the individual goals.  437 
The general discussion on management goals was quite comprehensive bringing 438 
several new elements to the discussion. From the hospital and pharmaceutical 439 
perspective, addressing and solving the problem of pharmaceuticals in the environment 440 
is very difficult, since much of the problem is related to human excretion, requires 441 
specialized treatment plant and cannot be solved by the sector. 442 
Although reconsidering of packaging sizes of pharmaceuticals is not in the 443 
sectoral goals, this goal was highlighted in the general discussions as a simple and 444 
efficient management measure, which in Brazil is not considered, there is no legislation 445 
that requires this of industry. It is known that packaging size can influence consumption, 446 
better serving users' needs and preventing the generation of unused and expired 447 
pharmaceuticals (BIO Intelligence Service 2013), for this some insdustries have already 448 
been working on this direction. The pharmaceutical sector stressed that the federal 449 
regulation should be modified in favor of this measure. In this way, the pharmaceuticals 450 
would not be stored unused at home. 451 
Collection of expired or discontinued pharmaceutical products was a much-452 
mentioned and discussed management initiative, both in sectoral goals and general 453 
discussions. Although there is clear progress in this regard, Brazil is still in an early phase 454 
of this management initiative (Aquino et al. 2018; Barcellos et al. 2019, p. 126; Rebehy 455 
et al. 2019). The feasible management goals that were agreed upon by each one of the 456 
four sectors participating in the event are presented in Tables 2, 3, 4 and 5. 457 
Table 2 - Distributors and pharmaceutical industries goals. 458 
*Goal nominated by sector as more important. 459 
Table 3 - Water industry goals. 460 
*Goal nominated by sector as more important. 461 
Table 4 – Pharmaceutical and hospital goals. 462 
*Goal nominated by sector as more important. 463 
Table 5 - Academic goals. 464 
*Goal nominated by sector as more important. 465 
The pharmaceutical sector stressed that through the Parana State pilot drug 466 
take-back program, which ended in 2017, 9.6 million kilograms of unused 467 
pharmaceuticals were collected. The participation of drugstores in Foz do Iguaçu, a city 468 
around 600 km far from Curitiba, where the population's adherence to the project was 469 
high, was highlighted as a success.  In Paraná, the law that regulates the drug take-back 470 
program came into force in July 2018, with, 270 collection points in operation and the 471 
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goal for 2019 is that further 500 points be installed. As State legislation covering drug 472 
take-back programmes is recent, the project under development is considered as pilot 473 
and is still in the test phase. The collection of pharmaceuticals is carried out for 60 474 
consecutive days at each location, after which the collection point is moved to another 475 
pharmacy. Collected pharmaceuticals are transported to an incineration plant in São 476 
Paulo, with support from the Union of Pharmaceutical Products Industry in the State of 477 
São Paulo (SINDUSFARMA).  478 
The pharmaceutical industry, on the other hand, reported having developed a 479 
separate, smaller scale project support with Union of the Chemical and Pharmaceutical 480 
Industries of the State of Paraná (SINQFAR-PR) whereby 60 pharmaceutical collection 481 
points have been established on a permanent basis in the State of Paraná. In the State 482 
of São Paulo, laws regulating the drug take-back program are of municipal scope, but 483 
are at a more incipient stage than what occurs in Parana State. The Federal Law Project 484 
that will be regulating this topic, and is currently in discussion in the National Congress, 485 
was also cited as essential for the expansion of drug take-back in Brazil. 486 
The representatives of the water industry suggested to the group, especially to 487 
the representatives of the pharmaceutical sector, that it would be useful to include in 488 
product packaging information about the impact of pharmaceutical residues on the 489 
environment and on human health. 490 
Participants from all sectors noted the absence of government stakeholders in 491 
the discussion. This constituted a gap in the intersectoral dialogue, as government 492 
institutions have a fundamental role in the introduction of public policies. It was noted 493 
that many of the measures targeted by the sectors can only be implemented if there is 494 
effective participation of the government. The need for synergy among sectors 495 
(government, water industry, pharmaceutical industries and distributors, hospitals and 496 
pharmacies, and academia sectors) was evident in the discussion for effective progress 497 
in the management of pharmaceutical micropollutants in Brazil. 498 
The water industry, represented by the Parana State Sanitation Company 499 
(SANEPAR), showed that these collaborative actions are indispensable for the sector due 500 
to the need for research technological advances that can only be developed with at least 501 
the support of academia. Its representatives also added that they would be very 502 
interested to open a more effective dialogue with the pharmaceutical sector to facilitate 503 
information exchange and enhance understanding of risk from pharmaceutical residues 504 
to the environment and to human health. 505 
Another discussion that was emphasized by the representatives of the water 506 
industry, considered the importance of establishing specific legislation to establish the 507 
monitoring of pharmaceuticals along with the establishment of safe concentration limits 508 
in river waters. A government representative in the first phase of the event also 509 
positioned himself in a favorable way to this, arguing that the periodic monitoring of 510 
these molecules is already financially viable, thus feasible. 511 
At the end of this second phase of discussions, Mentimeter® was used to assess  512 
stakeholders' perception regarding the timeframe necessary achieve a similar level of 513 
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control over pharmaceutical residues in the environment as is the case in some 514 
developed countries in Europe (United Kingdom, Germany, Netherlands, etc). Twelve 515 
out of the 22 participants answered the question (ten had to leave before the end of the 516 
plenary). Of the respondents, one answered that it would take "5 years", five answered 517 
"5 to 10 years", another 5 indicated that it would take "10 to 20 years" and one 518 
responded "more than 20 years". At this point, the pharmaceutical sector spoke up and 519 
said that the pharmaceutical industry must modify its production system in order to 520 
reduce pharmaceuticals in the environment. Another point touched was that the 521 
treatment of sewage is significant and should be prioritized because it reduces the 522 
pharmaceuticals in the environment. 523 
CONCLUSION 524 
The compounds prioritized (seven clearly had more importance) by the 525 
stakeholders in the workshop reflect the sectoral interests related to pharmaceutical 526 
pollution in the water and its management. The multidisciplinarity and multisectorality 527 
of the stakeholders present at the meeting ensured a comprehensive view of the 528 
problem, indicating which are the most important pharmaceuticals for management in 529 
the region of Curitiba and why they should be prioritized. On a national scale, these 530 
compounds are also likely to be important, but it is necessary to make efforts of 531 
prioritize in other regions because each region will have a different consumption pattern 532 
and, consequently, a different pollution pattern. 533 
The management goals are also important to think about and act towards the 534 
management of pharmaceutical micropollutants on the national scale and these are 535 
more generalizable than a list of priority substances. The multisectoral discussion about 536 
feasible actions showed that some initiatives priority have already started but are still 537 
emerging, as is the case of drug take-back program. Raising awareness amongst the 538 
population on the correct disposal of pharmaceuticals was defined as a priority goal, as 539 
were the technical and political aspects of implementation of the drug take-back 540 
program in Brazil. This issue is still a major challenge on a national scale and, due to its 541 
shared attribution, it is necessary to construct multisectoral networks and also have the 542 
participation of the population. Monitoring efforts to characterize the behavior of 543 
pharmaceuticals in the sanitation cycle and the creation of a permanent multisectoral 544 
environment for discussion on pharmaceutical micropollutants were the other two 545 
management goals prioritized. The new fronts of action and the challenges of each 546 
sector were also important elements of multisectoral discussion for enabling each sector 547 
to recognize the complexity of the problem and understand the need for a collective 548 
approach of problem, as already occurs in Europe (NOPILLS, 2015). 549 
However, the workshop represented an important initial step towards the 550 
management of pharmaceutical micropollutants in the Curitiba region and Brazil, being 551 
the first meeting with this multisectoral character in the country to discuss this type of 552 
pollution. In addition to the knowledge produced collectively, the most important legacy 553 
of this event was the formation of a network to discuss this problem and advance its 554 
management. The 37 stakeholders who participated in the event have great 555 
engagement in their sectors and relevant capacity for action. It is hoped that the 556 
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established network can be maintained and work collaboratively for the management 557 
of pharmaceutical micropollutants, as is it done successfully in Europe. 558 
The methodology used to conduct the workshop reached its objectives, 559 
producing collective knowledge in an interactively way, as well as informing and 560 
connecting people towards a common goal. This approach has shown promise for 561 
developing countries, such as those in Latin America, which are general still taking the 562 
first steps towards managing this kind of problem. 563 
SUPPLEMENTAL DATA  564 
The Supplemental Data contains: 1) the list with groups, institutions, total 565 
number of stakeholders preselected and those who participated of the event and; 2) the 566 
'long list' of initial pharmaceutical micropollutants made available to the stakeholders; 567 
3) frame of management initiatives made available to the stakeholders. 568 
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